Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab added to trastuzumab + docetaxel for first-line HER2-positive recurrent or metastatic breast cancer
2006-001365-42Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Bevacizumab + trastuzumab + docetaxel with Trastuzumab + docetaxel (2 arms). Primary endpoint: Progression-free survival. Started Jul 2006; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-001365-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001365-42.